• レポートコード:MRC2-11QY11363 • 出版社/出版日:QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態:英文、PDF、96ページ • 納品方法:Eメール(納期:2~3日) • 産業分類:ヘルスケア |
Single User | ¥585,000 (USD3,900) | ▷ お問い合わせ |
Multi User | ¥877,500 (USD5,850) | ▷ お問い合わせ |
Enterprise License | ¥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料は慢性特発性骨髄線維症のグローバル市場について調査・分析したレポートです。種類別(化学療法、生物学的療法、その他)市場規模、用途別(病院、クリニック、研究機関)市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別慢性特発性骨髄線維症の競争状況、市場シェア ・世界の慢性特発性骨髄線維症市場:種類別市場規模 2015年-2020年(化学療法、生物学的療法、その他) ・世界の慢性特発性骨髄線維症市場:種類別市場規模予測 2021年-2026年(化学療法、生物学的療法、その他) ・世界の慢性特発性骨髄線維症市場:用途別市場規模 2015年-2020年(病院、クリニック、研究機関) ・世界の慢性特発性骨髄線維症市場:用途別市場規模予測 2021年-2026年(病院、クリニック、研究機関) ・北米の慢性特発性骨髄線維症市場分析:米国、カナダ ・ヨーロッパの慢性特発性骨髄線維症市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの慢性特発性骨髄線維症市場分析:日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の慢性特発性骨髄線維症市場分析:メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの慢性特発性骨髄線維症市場分析:トルコ、サウジアラビア、UAE等 ・企業情報(企業概要、製品概要、販売量、企業動向) - 掲載企業(変更可能性あり):S-BIO、YM BioSciences、Sanofi、Onyx Pharmaceuticals ・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Idiopathic myelofibrosis is a chronic myelo-proliferative disorder and characterized by abnormal mutation of stem cells. This abnormal mutation of stem cells and excessive production of platelets result in development of fibrous tissues within the bone-marrow. This factor would ultimately negatively affect on the development of white blood cells (WBCs), red blood cells (RBCs) and platelets. The condition of idiopathic myelofibrosis may ultimately lead to the risk of acute myelogenous leukemia. Risk of idiopathic myelofibrosis is more in geriatric population as compared to children and adult population. Patients may develop symptoms such as weakness, weight loss, night sweats, hypertension and others. Blood chemistry tests, bone marrow aspiration, molecular testing and biopsy are useful diagnostic tools to diagnose and detect chronic idiopathic myelofibrosis. Patients with idiopathic myelofibrosis are advised to take drugs like hydroxyurea, interferon alfa, androgens, prednisone and others in order to treat this disorder. In addition, stem cell transplant and splenectomy is performed by physicians in severe cases of chronic idiopathic myelofibrosis.
The market of chronic idiopathic myelofibrosis is majorly driven by consistent efforts of key players to develop new and effective therapeutics. In addition, strategic collaboration and acquisition adopted by key players will further act as a driving factor for this market.
Market Analysis and Insights: Global Chronic Idiopathic Myelofibrosis Market
The global Chronic Idiopathic Myelofibrosis market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Chronic Idiopathic Myelofibrosis Scope and Market Size
Chronic Idiopathic Myelofibrosis market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Idiopathic Myelofibrosis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
S-BIO
YM BioSciences
Sanofi
Onyx Pharmaceuticals
…
Market segment by Type, the product can be split into
Chemotherapy
Biological Therapy
Others
Market segment by Application, split into
Hospitals
Clinics
Research Institutes
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Chronic Idiopathic Myelofibrosis Revenue
1.4 Market by Type
1.4.1 Global Chronic Idiopathic Myelofibrosis Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Biological Therapy
1.4.4 Others
1.5 Market by Application
1.5.1 Global Chronic Idiopathic Myelofibrosis Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Research Institutes
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Chronic Idiopathic Myelofibrosis Market Perspective (2015-2026)
2.2 Global Chronic Idiopathic Myelofibrosis Growth Trends by Regions
2.2.1 Chronic Idiopathic Myelofibrosis Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Chronic Idiopathic Myelofibrosis Historic Market Share by Regions (2015-2020)
2.2.3 Chronic Idiopathic Myelofibrosis Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Chronic Idiopathic Myelofibrosis Market Growth Strategy
2.3.6 Primary Interviews with Key Chronic Idiopathic Myelofibrosis Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Chronic Idiopathic Myelofibrosis Players by Market Size
3.1.1 Global Top Chronic Idiopathic Myelofibrosis Players by Revenue (2015-2020)
3.1.2 Global Chronic Idiopathic Myelofibrosis Revenue Market Share by Players (2015-2020)
3.1.3 Global Chronic Idiopathic Myelofibrosis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Chronic Idiopathic Myelofibrosis Market Concentration Ratio
3.2.1 Global Chronic Idiopathic Myelofibrosis Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Chronic Idiopathic Myelofibrosis Revenue in 2019
3.3 Chronic Idiopathic Myelofibrosis Key Players Head office and Area Served
3.4 Key Players Chronic Idiopathic Myelofibrosis Product Solution and Service
3.5 Date of Enter into Chronic Idiopathic Myelofibrosis Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Chronic Idiopathic Myelofibrosis Historic Market Size by Type (2015-2020)
4.2 Global Chronic Idiopathic Myelofibrosis Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020)
5.2 Global Chronic Idiopathic Myelofibrosis Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Chronic Idiopathic Myelofibrosis Market Size (2015-2020)
6.2 Chronic Idiopathic Myelofibrosis Key Players in North America (2019-2020)
6.3 North America Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020)
6.4 North America Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020)
7 Europe
7.1 Europe Chronic Idiopathic Myelofibrosis Market Size (2015-2020)
7.2 Chronic Idiopathic Myelofibrosis Key Players in Europe (2019-2020)
7.3 Europe Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020)
7.4 Europe Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020)
8 China
8.1 China Chronic Idiopathic Myelofibrosis Market Size (2015-2020)
8.2 Chronic Idiopathic Myelofibrosis Key Players in China (2019-2020)
8.3 China Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020)
8.4 China Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020)
9 Japan
9.1 Japan Chronic Idiopathic Myelofibrosis Market Size (2015-2020)
9.2 Chronic Idiopathic Myelofibrosis Key Players in Japan (2019-2020)
9.3 Japan Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020)
9.4 Japan Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Chronic Idiopathic Myelofibrosis Market Size (2015-2020)
10.2 Chronic Idiopathic Myelofibrosis Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020)
10.4 Southeast Asia Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020)
11 India
11.1 India Chronic Idiopathic Myelofibrosis Market Size (2015-2020)
11.2 Chronic Idiopathic Myelofibrosis Key Players in India (2019-2020)
11.3 India Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020)
11.4 India Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Chronic Idiopathic Myelofibrosis Market Size (2015-2020)
12.2 Chronic Idiopathic Myelofibrosis Key Players in Central & South America (2019-2020)
12.3 Central & South America Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020)
12.4 Central & South America Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 S-BIO
13.1.1 S-BIO Company Details
13.1.2 S-BIO Business Overview
13.1.3 S-BIO Chronic Idiopathic Myelofibrosis Introduction
13.1.4 S-BIO Revenue in Chronic Idiopathic Myelofibrosis Business (2015-2020))
13.1.5 S-BIO Recent Development
13.2 YM BioSciences
13.2.1 YM BioSciences Company Details
13.2.2 YM BioSciences Business Overview
13.2.3 YM BioSciences Chronic Idiopathic Myelofibrosis Introduction
13.2.4 YM BioSciences Revenue in Chronic Idiopathic Myelofibrosis Business (2015-2020)
13.2.5 YM BioSciences Recent Development
13.3 Sanofi
13.3.1 Sanofi Company Details
13.3.2 Sanofi Business Overview
13.3.3 Sanofi Chronic Idiopathic Myelofibrosis Introduction
13.3.4 Sanofi Revenue in Chronic Idiopathic Myelofibrosis Business (2015-2020)
13.3.5 Sanofi Recent Development
13.4 Onyx Pharmaceuticals
13.4.1 Onyx Pharmaceuticals Company Details
13.4.2 Onyx Pharmaceuticals Business Overview
13.4.3 Onyx Pharmaceuticals Chronic Idiopathic Myelofibrosis Introduction
13.4.4 Onyx Pharmaceuticals Revenue in Chronic Idiopathic Myelofibrosis Business (2015-2020)
13.4.5 Onyx Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Chronic Idiopathic Myelofibrosis Key Market Segments
Table 2. Key Players Covered: Ranking by Chronic Idiopathic Myelofibrosis Revenue
Table 3. Ranking of Global Top Chronic Idiopathic Myelofibrosis Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Chronic Idiopathic Myelofibrosis Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Biological Therapy
Table 7. Key Players of Others
Table 8. Global Chronic Idiopathic Myelofibrosis Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Chronic Idiopathic Myelofibrosis Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Chronic Idiopathic Myelofibrosis Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Chronic Idiopathic Myelofibrosis Market Share by Regions (2015-2020)
Table 12. Global Chronic Idiopathic Myelofibrosis Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Chronic Idiopathic Myelofibrosis Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Chronic Idiopathic Myelofibrosis Market Growth Strategy
Table 18. Main Points Interviewed from Key Chronic Idiopathic Myelofibrosis Players
Table 19. Global Chronic Idiopathic Myelofibrosis Revenue by Players (2015-2020) (Million US$)
Table 20. Global Chronic Idiopathic Myelofibrosis Market Share by Players (2015-2020)
Table 21. Global Top Chronic Idiopathic Myelofibrosis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Idiopathic Myelofibrosis as of 2019)
Table 22. Global Chronic Idiopathic Myelofibrosis by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Chronic Idiopathic Myelofibrosis Product Solution and Service
Table 25. Date of Enter into Chronic Idiopathic Myelofibrosis Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020) (Million US$)
Table 28. Global Chronic Idiopathic Myelofibrosis Market Size Share by Type (2015-2020)
Table 29. Global Chronic Idiopathic Myelofibrosis Revenue Market Share by Type (2021-2026)
Table 30. Global Chronic Idiopathic Myelofibrosis Market Size Share by Application (2015-2020)
Table 31. Global Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020) (Million US$)
Table 32. Global Chronic Idiopathic Myelofibrosis Market Size Share by Application (2021-2026)
Table 33. North America Key Players Chronic Idiopathic Myelofibrosis Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Chronic Idiopathic Myelofibrosis Market Share (2019-2020)
Table 35. North America Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020) (Million US$)
Table 36. North America Chronic Idiopathic Myelofibrosis Market Share by Type (2015-2020)
Table 37. North America Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020) (Million US$)
Table 38. North America Chronic Idiopathic Myelofibrosis Market Share by Application (2015-2020)
Table 39. Europe Key Players Chronic Idiopathic Myelofibrosis Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Chronic Idiopathic Myelofibrosis Market Share (2019-2020)
Table 41. Europe Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Chronic Idiopathic Myelofibrosis Market Share by Type (2015-2020)
Table 43. Europe Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Chronic Idiopathic Myelofibrosis Market Share by Application (2015-2020)
Table 45. China Key Players Chronic Idiopathic Myelofibrosis Revenue (2019-2020) (Million US$)
Table 46. China Key Players Chronic Idiopathic Myelofibrosis Market Share (2019-2020)
Table 47. China Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020) (Million US$)
Table 48. China Chronic Idiopathic Myelofibrosis Market Share by Type (2015-2020)
Table 49. China Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020) (Million US$)
Table 50. China Chronic Idiopathic Myelofibrosis Market Share by Application (2015-2020)
Table 51. Japan Key Players Chronic Idiopathic Myelofibrosis Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Chronic Idiopathic Myelofibrosis Market Share (2019-2020)
Table 53. Japan Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Chronic Idiopathic Myelofibrosis Market Share by Type (2015-2020)
Table 55. Japan Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Chronic Idiopathic Myelofibrosis Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Chronic Idiopathic Myelofibrosis Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Chronic Idiopathic Myelofibrosis Market Share (2019-2020)
Table 59. Southeast Asia Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Chronic Idiopathic Myelofibrosis Market Share by Type (2015-2020)
Table 61. Southeast Asia Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Chronic Idiopathic Myelofibrosis Market Share by Application (2015-2020)
Table 63. India Key Players Chronic Idiopathic Myelofibrosis Revenue (2019-2020) (Million US$)
Table 64. India Key Players Chronic Idiopathic Myelofibrosis Market Share (2019-2020)
Table 65. India Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020) (Million US$)
Table 66. India Chronic Idiopathic Myelofibrosis Market Share by Type (2015-2020)
Table 67. India Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020) (Million US$)
Table 68. India Chronic Idiopathic Myelofibrosis Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Chronic Idiopathic Myelofibrosis Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Chronic Idiopathic Myelofibrosis Market Share (2019-2020)
Table 71. Central & South America Chronic Idiopathic Myelofibrosis Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Chronic Idiopathic Myelofibrosis Market Share by Type (2015-2020)
Table 73. Central & South America Chronic Idiopathic Myelofibrosis Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Chronic Idiopathic Myelofibrosis Market Share by Application (2015-2020)
Table 75. S-BIO Company Details
Table 76. S-BIO Business Overview
Table 77. S-BIO Product
Table 78. S-BIO Revenue in Chronic Idiopathic Myelofibrosis Business (2015-2020) (Million US$)
Table 79. S-BIO Recent Development
Table 80. YM BioSciences Company Details
Table 81. YM BioSciences Business Overview
Table 82. YM BioSciences Product
Table 83. YM BioSciences Revenue in Chronic Idiopathic Myelofibrosis Business (2015-2020) (Million US$)
Table 84. YM BioSciences Recent Development
Table 85. Sanofi Company Details
Table 86. Sanofi Business Overview
Table 87. Sanofi Product
Table 88. Sanofi Revenue in Chronic Idiopathic Myelofibrosis Business (2015-2020) (Million US$)
Table 89. Sanofi Recent Development
Table 90. Onyx Pharmaceuticals Company Details
Table 91. Onyx Pharmaceuticals Business Overview
Table 92. Onyx Pharmaceuticals Product
Table 93. Onyx Pharmaceuticals Revenue in Chronic Idiopathic Myelofibrosis Business (2015-2020) (Million US$)
Table 94. Onyx Pharmaceuticals Recent Development
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Idiopathic Myelofibrosis Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Biological Therapy Features
Figure 4. Others Features
Figure 5. Global Chronic Idiopathic Myelofibrosis Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Research Institutes Case Studies
Figure 9. Chronic Idiopathic Myelofibrosis Report Years Considered
Figure 10. Global Chronic Idiopathic Myelofibrosis Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Chronic Idiopathic Myelofibrosis Market Share by Regions: 2020 VS 2026
Figure 12. Global Chronic Idiopathic Myelofibrosis Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Chronic Idiopathic Myelofibrosis Market Share by Players in 2019
Figure 15. Global Top Chronic Idiopathic Myelofibrosis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Idiopathic Myelofibrosis as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Chronic Idiopathic Myelofibrosis Revenue in 2019
Figure 17. North America Chronic Idiopathic Myelofibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Chronic Idiopathic Myelofibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Chronic Idiopathic Myelofibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Chronic Idiopathic Myelofibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Chronic Idiopathic Myelofibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Chronic Idiopathic Myelofibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Chronic Idiopathic Myelofibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed